Angiotensin II Type I Receptor Antagonist Losartan Reduces Apoptosis of Cardiomyocytes

齐丽彤,张钧华,李大元,周爱儒
DOI: https://doi.org/10.3760/j:issn:0253-3758.2001.02.016
2001-01-01
Abstract:Objective To test the effect of angiotensin II type I receptor antagonist losartan on myocyte apoptosis and expression of P53 and Bcl-2 in myocardium of ischemia-reperfusion rat model. Methods Wistar rats were randomly divided into three groups:(1) Control group (n=5); (2) Ischemia-reperfusion group(n=6); the left coronary artery was occluded for 45 min followed by 4 hours reperfusion; (3) Losartan group (n=6):losartan (10mg/kg)were given intravenously 15 min before occlusion and 1 hour after the initiation of reperfusion. DNA ladder and TUNEL were used to detect apoptotic myocytes. P53 and Bcl-2 expression in myocardium were analyzed by immunohistochemical technique. Results The number of apoptotic myocytes of losartan group were 63.6% less than that of ischemia-reperfusion group [(10.3±2.1)% vs. (28.4±1.4)%, P<0.01]. Ischemia-reperfusion induced P53 expression in myocardium, which could be inhibited by losartan. The expression of Bcl-2 in myocardium were significantly increased in losartan group. Conclusion Angiotensin II type I receptor antagonist losartan could diminish cardiomiocyte apoptosis induced by ischemia-reperfusion, reduce P53 expression and increase Bcl-2 expression in myocardium.
What problem does this paper attempt to address?